Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation and Depletion (2016 - 2023)

Rocket Pharmaceuticals' Depreciation and Depletion history spans 8 years, with the latest figure at $1.2 million for Q3 2023.

  • For Q3 2023, Depreciation and Depletion rose 6.64% year-over-year to $1.2 million; the TTM value through Sep 2023 reached $1.4 million, down 60.92%, while the annual FY2022 figure was $800000.0, N/A changed from the prior year.
  • Depreciation and Depletion for Q3 2023 was $1.2 million at Rocket Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.2 million in Q2 2023 and bottomed at -$2.1 million in Q4 2022.
  • The 5-year median for Depreciation and Depletion is $444000.0 (2019), against an average of $410142.9.
  • The largest annual shift saw Depreciation and Depletion changed 0.0% in 2020 before it soared 47.98% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $101000.0 in 2019, then decreased by 0.99% to $100000.0 in 2020, then soared by 700.0% to $800000.0 in 2021, then plummeted by 358.38% to -$2.1 million in 2022, then skyrocketed by 156.75% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for RCKT's Depreciation and Depletion are $1.2 million (Q3 2023), $1.2 million (Q2 2023), and $1.1 million (Q1 2023).